Trial Profile
A Non-interventional Protocol to Collect Prospective and Retrospective Data in Patients Receiving Everolimus to Prevent Acute Rejection Following Cardiac Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2011
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 20 Jun 2011 New trial record